Novartis Challenges Gleevec Patent Block In India
Less than a year after India's Patent Controller denied Novartis AG's patent application for the cancer treatment Gleevec, the Swiss-based pharmaceutical company is railing against the rejection....To view the full article, register now.
Already a subscriber? Click here to view full article